Collegium Q2 revenue rises 29% to $188.0 million; raises 2025 revenue guidance
Collegium reported second-quarter 2025 product revenue of $188.0 million, up 29% from a year earlier, and raised its full-year 2025 product revenue guidance to $745 million to $760 million. GAAP net income fell to $12.0 million, or $0.34 per diluted share, from $19.6 million, or $0.52, a year earlier, as operating expenses rose. The company also authorized a $150 million share repurchase program running through December 31, 2026.
Key points
- Q2 2025 product revenue of $188.0 million, up 29% year over year; Jornay PM net revenue of $32.6 million, with prescriptions up 23%
- Full-year 2025 product revenue guidance raised to $745 million to $760 million, from $735 million to $750 million; adjusted EBITDA guidance raised to $440 million to $455 million
- GAAP net income of $12.0 million ($0.34 diluted EPS) for Q2 2025, versus $19.6 million ($0.52) for Q2 2024
- Board authorized a $150 million share repurchase program through December 31, 2026; cash and marketable securities were $222.2 million at June 30, 2025
The filing
Written by AI on Nov 8, 2026, 2:07 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.